ALL SPONSORED PRESENTATIONS ARE NON-CME
MONDAY, DECEMBER 7, 2020 | 7:00 pm – 8:00 pm EST
The Next Horizon in the Heart Failure Treatment Paradigm for Patients With HFrEF
SPEAKER: Karthik Linganathan, MD
Learning Objectives:
- Highlight the prevalence, burden, and risk of heart failure in the United States
- Review the indications, limitations for use, and contraindications for dapagliflozin
- Understand the effects of dapagliflozin in patients with heart failure-reduced ejection fraction (HFrEF)
- Describe the effects of dapagliflozin on HF-related outcomes
- Discuss practical considerations regarding the use of SGLT2 inhibitors
- Understand the stepwise approach to the use of dapagliflozin in patients with HFrEF at risk for CV death or hospitalization for heart failure
SPONSORED BY: AstraZeneca
TUESDAY, DECEMBER 8, 2020 | 12:30 pm – 1:15 pm EST
An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C
SPEAKER: Guy L. Mintz, MD, FACC, FACP, FNLA, FASPC
The session will cover the following information:
- Cardiovascular disease and its mortality and morbidity
- Unique mechanism of action for two treatment options
- Efficacy data for two treatment options
- Safety data for two treatment options
- Overview of the ongoing Outcomes trial
SPONSORED BY: Esperion Therapeutics
THURSDAY, DECEMBER 10, 2020 | 12:30 pm – 1:30 pm EST
Clinical Considerations in Stroke or Transient Ischemic Attack
SPEAKER: John Venditto, MD, MBA, FACC
Learning Objectives:
- Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
- Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
- Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial
SPONSORED BY: AstraZeneca
MONDAY, DECEMBER 14, 2020 | 7:00 pm – 7:45 pm EST
An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C
SPEAKER: Jan L. McAlister, DNP, APRN, CLS
The session will cover the following information:
- Cardiovascular disease and its mortality and morbidity
- Unique mechanism of action for two treatment options
- Efficacy data for two treatment options
- Safety data for two treatment options
- Overview of the ongoing Outcomes trial
SPONSORED BY: Esperion Therapeutics
THURSDAY, DECEMBER 17, 2020 | 12:30 pm – 1:30 pm EST
Clinical Considerations across the Spectrum of High Risk Coronary Artery Disease and Stroke
SPEAKER: John Venditto, MD, MBA, FACC
The session will cover the following information:
- Describing the risk spectrum across the spectrum of CAD
- The role of platelets across the spectrum of CAD
- The role of antiplatelets in patients with CAD at high risk of CV events, ACS and patients with a history of MI.
SPONSORED BY: AstraZeneca
Register for a sponsored presentation now to receive 50% off of your full conference registration and we'll match your donation. You will receive your discount code upon completing your sponsored presentation registration.